Scott W. Cousins, MD
Vice-chair, Research, Department of Ophthalmology
Departments / Divisions- Ophthalmology / Ophthalmology-General
- Immunology
Address
DUMC 3802
Durham, NC 27710
Appointment Telephone
919-681-3937
Office Telephone
919-684-6611
Fax Telephone
919-681-6474
- MD, Case Western Reserve University School of Medicine (Ohio), 1982
- Ophthalmology, Washington University/Barnes Hospital (Missouri), 1983-1986 (Chief Resident, 1987-1988)
- Vitreoretinal Fellow, Bascom Palmer Eye Institute (Florida), 1986-1987
Clinical Interests
Diagnosis, treatment and research of macular diseases, especially AMD; diabetic retinopathy and retinal vascular disease
Research Interests
Scott W. Cousins, M.D. is currently the Robert Machemer, M.D. Professor of Ophthalmology and Immunology, Vice Chair for Research, and Director of the Duke Center for Macular Diseases at Duke Eye Center. As Vice Chair, he oversees all basic science research as well as the Ophthalmology Site-Based Research Group, which administrates clinical research for Duke Eye Center. Dr. Cousins is also Medical Director of Hospital-Based Imaging and Procedures for Duke Eye Center.
Dr. Cousins is a retina-trained ophthalmologist who specializes in the diagnosis and treatment of macular diseases, especially age-related macular degeneration (AMD), diabetic retinopathy, and retinal vascular diseases. Dr. Cousins is active in both clinical and laboratory research. In his clinical practice, Dr. Cousins is involved in many trials and innovative therapies for the treatment of macular diseases, especially AMD and diabetic retinopathy. He has served as site PI for numerous phase1-3 clinical trials in AMD, diabetic retinopathy, and other retinal disorders. He has served as a consultant or member of data safety monitoring committees (DSMC) for numerous pharmaceutical and biotechnology startup companies.
In his scientific laboratory, Dr. Cousins pursues both NIH-funded and industry-funded research in various areas of dry and wet AMD. In particular, he is studying the role of circulating bone marrow-derived progenitors (stem cells) in contributing to wet AMD. His laboratory is attempting to develop treatments for dry macular degeneration and improving vision in eyes with wet macular degeneration. His program is also developing blood tests and new imaging technologies for the identification of patients who are at high risk for progressing into complications.
Dr. Cousins has published over 100 peer-reviewed manuscripts, book chapters, and other publications addressing topics of research or clinical care of retinal disease, especially AMD. In 2006, Dr. Cousins was awarded the prestigious Alcon Research Foundation Clinician Scientist Award. In 2008, the National Institutes of Health invited Dr. Cousins to join the National Advisory Eye Council. Dr. Cousins is also a member of the American Academy of Ophthalmology, the American Society of Retina Specialists, the Retina Society, the Association for Research in Vision and Ophthalmology, the American Association of Immunologists, and the American Medical Association.
In 2010, Dr. Cousins was named one of the “Top 34 Ophthalmologists in the United States” by Becker’s ASC Review, a leading source of business and legal news for ambulatory surgery centers. They cited his leadership of the Duke Center for Macular Diseases and his ongoing research in macular degeneration as reasons for the honor.
This physician (or a member of their immediate family) has a working relationship (i.e. consulting, research, and/or educational services) with the companies listed below. These relations have been reported to the health system leadership and, when appropriate, management plans are in place to address potential conflicts.
- Allergan, Inc.
- Apeliotus Engineering
- Eyetech Pharmaceuticals (OSI Pharmaceuticals)
- Fovea Pharma
- Genentech, Inc (Roche Holding)
- Heidelberg Engineering
- Novartis
- Ophthotech
- Pfizer Inc.
- QLT
- ViroPharma Inc.
